First AD

Second AD

Elafibranor and Choosing Amongst PPAR Agonists in PBC

Video content above is prompted by the following:

The FDA recently approved another PPAR-δ agonist, elafibranor, for PBC. Could you discuss the long-term data of this agent? 

How do clinical findings for elafibranor compare with those of seladelpar?

How do you choose the right PPAR agonist for treating PBC, and how do you know if the treatment is working?

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Video Series

Expanding Treatment Options for Primary Biliary Cholangitis with Novel Therapies

Elafibranor, a PPAR-δ agonist, has been approved by the FDA for primary biliary cholangitis (PBC), showing promising long-term efficacy and safety data. Clinical findings indicate that elafibranor and seladelpar both improve liver function and reduce symptoms in PBC patients, but they differ in their receptor selectivity and side effect profiles. Choosing the appropriate PPAR agonist involves considering patient-specific factors, such as comorbidities and tolerance to side effects. Monitoring treatment efficacy involves regular assessment of liver function tests and symptom improvement to ensure optimal patient outcomes.

The panel of experts examine the long-term data for the recently FDA-approved PPAR-δ agonist elafibranor in the treatment of primary biliary cholangitis (PBC), comparing its clinical findings with those of seladelpar, and explores how to choose the right peroxisome proliferator-activated receptor (PPAR) agonist and assess treatment effectiveness.